201 Elliott Avenue West
United States - Map
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes products targeting inflammation, coagulopathies, and disorders of the central nervous system. Its clinical products include Omidria, which has completed two Phase III clinical trials for use during intraocular lens replacement, including cataract and other lens replacement surgery; OMS103 that is in Phase III clinical program for use during arthroscopic procedures, such as partial meniscectomy surgery; and OMS824, which is in Phase II clinical trial for the treatment of CNS disorders comprising schizophrenia and Huntington's disease. Its clinical programs also consist of OMS721 that is in Phase II clinical trial for the treatment of various complement-related diseases and disorders, including thrombotic microangiopathies; OMS405, which is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase 1/Phase 2 clinical trial for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The companys preclinical products and development programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; and OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions. Its preclinical products also include G protein-coupled receptors platform for multiple disorders across therapeutic area; GPR17 for demyelinating disorders; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
|Omeros Corporation’s ISS Governance QuickScore as of Aug 1, 2014 is 9. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 6; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Gregory A. Demopulos M.D.,
Co-Founder, Chairman, Chief Exec. Officer and Pres
|Mr. Michael A. Jacobsen ,
Principal Financial Officer, Chief Accounting Officer, VP of Fin. and Treasurer
|Ms. Marcia S. Kelbon Esq., J.D., M.S.,
VP of Patent, Gen. Counsel and Sec.
|Dr. George A. Gaitanaris M.D., Ph.D.,
Chief Scientific Officer and VP of Science
|Dr. Kenneth M. Ferguson Ph.D.,
Chief Devel. Officer and VP of Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|